window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Antimicrobial Resistance

  • Clinical studies,Dermatology,Medical devices

    Laser therapy reduces bacterial load in burn wounds, study shows

    A single photobiomodulation session reduced bacterial load in acute burn [...]

    March 3, 2026
  • Biologics & Biosimilars,Clinical Development,Clinical studies,Global health,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    PACE launches third funding round to tackle antimicrobial resistance and support innovative therapeutics

    PACE (Pathways to Antimicrobial Clinical Efficacy) has launched its third [...]

    October 1, 2025
  • CDMOs & Manufacturing,Drug Development,Partnerships & Funding,Rare Diseases

    Shionogi and BioVersys agree €498M licensing deal for NTM drug candidates

    Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]

    July 2, 2025
  • Drug Development

    Study shows bifunctional immunotherapy clears MDR Gram-negative bacteria in preclinical models

    CTX-09 demonstrates immune-mediated efficacy through Alphamer platform, supporting immune system [...]

    June 10, 2025
  • Clinical Trials

    Cefiderocol shows improved outcomes when used earlier in treatment pathway, new European data reveals

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top